Pinaverium Drug Offers Quick Relief to Patients Suffering From Irritable Bowel Syndrome

by Bidita Debnath on  July 2, 2015 at 12:32 AM Research News
RSS Email Print This Page Comment
Font : A-A+

Pinaverium shows promising results for the treatment of irritable bowel syndrome (IBS), shows a new study. Pinaverium bromide (pinaverium), an antispasmodic, is used widely in many countries around the world, including European countries, Canada and Mexico.
 Pinaverium Drug Offers Quick Relief to Patients Suffering From Irritable Bowel Syndrome
Pinaverium Drug Offers Quick Relief to Patients Suffering From Irritable Bowel Syndrome

However, original clinical studies on pinaverium are scarce and there has been no convincing evidence for its effectiveness and safety. As such, the U.S. Food and Drug Administration (FDA) has not approved this treatment for use in the U.S. Lead study author Liang Zheng from the Nanjing University of Chinese Medicine said that there is no cure for IBS and no gold standard of treatment.

To help the patients suffering from this disorder, they need to gather reliable data to evaluate the effectiveness and safety profile of new treatment options. Zheng added that this study confirms that pinaverium is an effective and safe option for IBS patients, making it a viable first-line therapy for patients. Hopefully, our findings will help FDA in its evaluation of pinaverium to potentially bring this drug to patients in the U.S.

A significantly higher percentage of patients receiving pinaverium reported that their IBS symptoms improved (60%) than in the placebo group (34%). In the pinaverium group, 29% of patients believed that their IBS symptoms stayed the same and 11% said they worsened.

Pinaverium was not associated with severe adverse effects; common side effects included nausea (3.7%), dizziness (3.2%), increased blood pressure (2.3%) and abdominal discomfort (2.3%). IBS is the most common chronic (life-long in some patients) and highly recurrent gastrointestinal disorder, with an estimated worldwide prevalence of 10 to 15%.

The study is published in Clinical Gastroenterology and Hepatology.

Source: ANI

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Constipation Signature Drug Toxicity Crohns Disease Irritable Bowel Syndrome Pelvic Pain in Women Constipation-Symptom Evaluation Abdominal Distension Modified Atkins Diet: All You Need to Know 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive